FVFilip Velickovic

Filip Velickovic

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Filip Velickovic has a total of 13 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Investigation of Colonic Transit in Constipated Adults Using 99mTc—DTPA—Carbo Medicinalis Labeled Meal

    by Milos Stevic, Ivana Misic, Filip Velickovic, Tamara Andjelkovic, Goran Stanojevic

    Background and Objectives: Constipation is a common problem in the general population. About 15% of the population suffers from one of the defecation disorders caused by various etiological factors. The goal of this work was the implementation of scintigraphic evaluation of colonic transit in patients with constipation. Materials and Methods: A total of 117 patients were examined (68 (58%) women and 49 (42%) men, in whom the existence of constipation was determined in the previous period by self-evaluation and using the ROMA IV criteria. All patients were given an oral test meal containing 99mTc-labeled charcoal in a dose of 370 MBq. Targeted static scintigrams were performed 8, 24, and 48 hours after the application of the test meal in the anterior projection over the abdomen. All scintigrams were qualitatively examined, and after the qualitative assessment, the geometric center (GC) of the radiopharmaceutical distribution was calculated. Results: Generalized slowing of colonic transit was detected in 85% of women while 15% of female subjects showed both qualitatively and GC-estimated normal colonic transit. In men, slowed colonic transit was detected in 78% of examined patients, while 22% of patients had qualitatively normal colonic transit and GC that fell within normal values. Idiopathic constipation was detected in 85% of women and 88% of men. A smaller number of patients showed the existence of etiological factors for slowed colonic transit. Conclusions: Scintigraphic evaluation of colonic transit using 99mTc-DTPA-labeled medical charcoal has proven to be an easy-to-perform, non-invasive method by which it is possible to detect the presence of slowing of colonic transit. In addition to the qualitative assessment of the obtained scintigrams, quantification by calculating the geometric center enables an even more precise insight into the assessment of the segment of the large intestine in which the slowing of colonic transit occurred.

  • Open Access

    Expression of Basal Compartment and Superficial Markers in Upper Tract Urothelial Carcinoma Associated with Balkan Endemic Nephropathy, a Worldwide Disease

    by Ljubinka Jankovic Velickovic, Ana Ristic Petrovic, Zana Dolicanin, Slavica Stojnev, Filip Velickovic, Dragoslav Basic

    The aim of this study was to determine the association of basal compartment and superficial markers, comprising CK5/6, CD44, CK20, and the pathological characteristics of upper tract urothelial carcinoma (UTUC) associated with Balkan endemic nephropathy (BEN). Comparing the expression of the investigated markers in 54 tumors from the BEN region and 73 control UTUC, no significant difference between them was detected. In regression analysis, CK20 expression was not determined with expression of CK5/6, CD44, and the phenotypic characteristics of BEN and control UTUC. Parameters with predictive influence on the expression of CD44 in BEN UTUC included growth pattern (p = 0.010), necrosis (p = 0.019); differentiation (p = 0.001), and lymphovascular invasion (p = 0.021) in control UTUC. Divergent squamous differentiation in BEN tumors (p = 0.026) and stage in control tumors (p = 0.049) had a predictive influence on the expression of CK5/6. This investigation detected a predictive influence of the phenotypic characteristics of UTUC on the expression of basal compartment and superficial markers, with a significant influence of necrosis in BEN tumors (p = 0.006) and differentiation in control UTUC (p = 0.036).


  • Open Access

    Theranostics and precision medicine In neuroendocrine tumors

    by Filip Veličković, Marina Vlajković, Miloš Stević, Nina Topić, Tamara Anđelković, Đuro Macut

    Neuroendocrine tumors (NETs) have increased expression of somatostatin receptors (SSTR), where subtype 2 and 5 are the most common. Overexpression of the SSTR is an outstanding molecular target for inoperable and metastatic NETs that enables a unique approach of targeted diagnosis and treatment. In addition to SSTRs, neuroendocrine tumors also express other receptors that can be suitable targets for visualization by nuclear medicine methods. This review paper is focused on the most common radiopharmaceuticals and their molecular targets that are used today based on theranostic approach in NETs. In conventional nuclear medicine, the most important diagnostic radiopharmaceuticals are somatostatin analogs (SSA) labeled with 111 In and 99m Tc, however 99m Tc has advantages over 111 In based on better physical characteristics and better performance. In recent years, highly potent theranostic pairs have been created for the imaging and treatment of NETs, which can strongly bind SSTR. Derivatives of 68 Ga-labeled octreotide are recommended for diagnostics and follow-up of NENs. The great advantage of 68 Ga radiopharmaceuticals is that identical compounds can be labeled with therapeutic radionuclides 90 Y and 177 Lu. Peptide receptor radionuclide therapy is a systemic molecular target therapy that has proven to be safe and very effective in controlling the disease and prolonging the survival of patients with advanced and inoperable NETs. With a negligible number of adverse events, this therapy is safe and should be administered to all patients who meet the necessary criterias, primarily overexpression of the somatostatin receptor type 2.